None listed
Conditions
Brief summary
Glaucoma is a progressive disease of the optic nerve, which if undiagnosed, can lead to blindness. Surgery is often reserved for very severe cases and as such, surgical success is imperative. Our project will address this by performing a randomised double blinded assessment of the adjunctive use of intraoperative intravitreal bevacizumab (Avastin), a currently available and widely used anti-VEGF drug, on post-operative glaucoma surgery success. If this intervention is successful, the outcomes could undoubtedly influence future surgical management.
Interventions
A single intraoperative intravitreal injection of bevacizumab 1.25mg in 0.05ml
Sponsors
A/Prof John Landers
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
40 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
Those requiring a trabeculectomy or a phaco-trabeculectomy based on the judgement of the treating surgeon
Exclusion criteria
Anterior segment dysgenesis, irido-corneal-endothelial syndrome, proliferative diabetic retinopathy, congenital or juvenile-onset glaucoma, traumatic glaucoma, rubeotic glaucoma, previous corneal graft surgery, previous vitrectomy surgery requiring silicone oil, any condition for which the patient is currently receiving intravitreal anti-VEGF medication. However, previous cataract or trabeculectomy surgery is not an exclusion.
Outcome results
None listed